Moreover, IGF2BP3 is upregulated and its high expression conveys tumor progression and worse prognosis in patients with lung adenocarcinoma [99], esophageal cancer [100], gastric cancer [63], pancreatic adenocarcinoma [101], papillary renal cell carcinoma [102], colon cancer [56], clear cell renal cell carcinoma [61], bladder cancer [103], prostate cancer [104], nasopharyngeal carcinoma [64], laryngeal squamous cell cancer [60], melanoma [105], glioma [106], acute myelocytic leukemia [65], among others. Here, IGF2BP3 is linked to acute myeloid leukemia.